PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer
- Status
- RECRUITING
- Phase
- NA
Clinical Trials Related to Hepatocellular Carcinoma
Related studies linked through entity extraction aliases.
Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy
- Status
- COMPLETED
- Phase
- PHASE2
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
FAST-IRM for HCC suRveillance in pAtients With High risK of Liver Cancer.
- Status
- RECRUITING
- Phase
- NA
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Role of DEB-TACE Versus c-TACE in Treatment of HCC
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
- Status
- TERMINATED
- Phase
- PHASE1
The Role of Long Non-coding RNAs WRAP53 and UCA-1 as Potential Biomarkers in Diagnosis of Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- N/A
Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA)
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
- Status
- RECRUITING
- Phase
- PHASE3
Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- NA
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Role of Perfluorobutane in Lesion Detection, Targeting and Response Assessment for Ablation of HCC
- Status
- COMPLETED
- Phase
- NA
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
TheraSphere With Durvalumab and Tremelimumab for HCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Personalized Cancer Vaccine in Egyptian Cancer Patients
- Status
- UNKNOWN
- Phase
- PHASE1
Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC
- Status
- UNKNOWN
- Phase
- PHASE3
Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- NA
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2